Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis

Galderma

Status and phase: Completed; Phase 4

Conditions: Plaque Psoriasis

Treatments: Drug: Calcipotriene and betamethasone dipropionate ointment; Drug: Clobetasol Propionate, 0.05%

Study type: Interventional

Funder types: Industry

Identifiers

NCT00437255

US10034

Details and patient eligibility

About

Evaluate the efficacy of Clobex® Spray as compared to Taclonex® Ointment in terms of Overall Disease Severity and Investigator Global Assessment.

Full description

Same as above.

Enrollment: 122 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Moderate to severe psoriasis involving 3-20% of the body surface area

Exclusion criteria

• Subjects who have surface area involvement too large that would require more than 50 grams per week of Clobex® Spray or more than 100 grams per week of Taclonex® Ointment
• Subjects having psoriasis that involves the scalp, face, or groin

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

122 participants in 2 patient groups

1

Active Comparator group

Description:

Clobex® Spray

Treatment:

Drug: Clobetasol Propionate, 0.05%

2

Active Comparator group

Description:

Taclonex® Ointment

Treatment:

Drug: Calcipotriene and betamethasone dipropionate ointment